Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Autologous osteoblastic cell therapy - BioSenic

Next Previous
Drug Profile

Autologous osteoblastic cell therapy - BioSenic

Alternative Names: Autologous-osteoblastic-cells-BioSenic; Autologous-pre-osteoblast-cell-therapy-BioSenic; Autologous-pre-osteoblastic-cell-therapy-BioSenic; Autologous-preosteoblastic-cells-BioSenic; PREOB; PREOB cells; PREOB-NU; PREOB-ON

Latest Information Update: 03 Nov 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bone Therapeutics
  • Developer BioSenic
  • Class Cell therapies
  • Mechanism of Action Cell replacements; Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Femur head necrosis
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Femur head necrosis; Non-union fracture; Osteoporosis

Most Recent Events

  • 25 Oct 2022 Medsenic has been acquired by Bone Therapeutics and the later changed its name to BioSenic
  • 06 Nov 2018 Bone Therapeutics terminates phase III trial in Femur head necrosis in United Kingdom, Belgium, France, Germany and Netherlands as per the recommendation from the DSMB
  • 20 Oct 2017 Bone Therapeutics terminates a phase II/III trial in Non-union fracture in Belgium, France and Netherlands to focus resources in the allogeneic platform and provide optimal value for patients (Intraosseous) (NCT01756326)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top